Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Operating Margin (2016 - 2025)

Historic Operating Margin for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to 173.3%.

  • Marker Therapeutics' Operating Margin fell 487000.0% to 173.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 876.6%, marking a year-over-year increase of 10403200.0%. This contributed to the annual value of 5559.19% for FY2024, which is 51188100.0% down from last year.
  • As of Q3 2025, Marker Therapeutics' Operating Margin stood at 173.3%, which was down 487000.0% from 494.79% recorded in Q2 2025.
  • Marker Therapeutics' 5-year Operating Margin high stood at 93.29% for Q4 2024, and its period low was 1320.14% during Q1 2025.
  • Its 4-year average for Operating Margin is 482.66%, with a median of 400.28% in 2022.
  • Its Operating Margin has fluctuated over the past 5 years, first surged by 11176200bps in 2024, then crashed by -11152500bps in 2025.
  • Over the past 4 years, Marker Therapeutics' Operating Margin (Quarter) stood at 400.28% in 2022, then soared by 31bps to 278.06% in 2023, then soared by 134bps to 93.29% in 2024, then crashed by -286bps to 173.3% in 2025.
  • Its Operating Margin stands at 173.3% for Q3 2025, versus 494.79% for Q2 2025 and 1320.14% for Q1 2025.